Diabetes medicine sales in Canada reached CAD 4.91 billion in 2023, marking a robust compound annual growth rate (CAGR) of 15.39% over the past five years. The year-on-year growth has generally been strong, peaking at 21.58% in 2022. Looking ahead, the market is forecasted to grow with a moderate CAGR of 7.4%, reaching CAD 7.94 billion by 2028.

Future trends to watch for include:

Innovation in diabetes treatment, including advanced drug delivery systems and personalized medicine.
Government healthcare policies and their impact on market dynamics.
The increasing prevalence of diabetes and its implications for market demand.
Potential pricing pressures from healthcare payers and generic drug competition.